Last reviewed · How we verify

NCT05973929

Movement Disorders in Multiple Sclerosis Patients

Status unknown Last updated 14 August 2023
What this trial tests

trial testing Screen for movement disorder and correlates it with MRI findings. in Multiple Sclerosis in 57 participants. Status unknown.

Timeline
22 September 2022
Primary endpoint
21 March 2024
1 May 2024

Quick facts

Lead sponsorAl-Azhar University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment57
Start date22 September 2022
Primary completion21 March 2024
Estimated completion1 May 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 18 to 55, any sex, with Multiple Sclerosis or Movement Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the prevalence of movement disorders in MS patients. Also,To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients. Moreover, to find the correlation between the movement disorder and the different types of MS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05973929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing